These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32269572)

  • 1. Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.
    Fitzpatrick EA; Wang J; Strome SE
    Front Immunol; 2020; 11():496. PubMed ID: 32269572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
    Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
    J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.
    Nagelkerke SQ; Dekkers G; Kustiawan I; van de Bovenkamp FS; Geissler J; Plomp R; Wuhrer M; Vidarsson G; Rispens T; van den Berg TK; Kuijpers TW
    Blood; 2014 Dec; 124(25):3709-18. PubMed ID: 25352126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dual Targeting of FcRn and FcγRs
    Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
    Front Immunol; 2021; 12():728322. PubMed ID: 34512662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation Fc receptor-targeting biologics for autoimmune diseases.
    Zuercher AW; Spirig R; Baz Morelli A; Rowe T; Käsermann F
    Autoimmun Rev; 2019 Oct; 18(10):102366. PubMed ID: 31404703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
    Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
    Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
    Anthony RM; Ravetch JV
    J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IVIG in autoimmune disease - Potential next generation biologics.
    Zuercher AW; Spirig R; Baz Morelli A; Käsermann F
    Autoimmun Rev; 2016 Aug; 15(8):781-5. PubMed ID: 27019051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation.
    Mimura Y; Mimura-Kimura Y; Saldova R; Rudd PM; Jefferis R
    Front Immunol; 2022; 13():818382. PubMed ID: 35154135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
    Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
    J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
    Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
    Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
    Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
    Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
    Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
    J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases.
    Karsten CM; Köhl J
    Immunobiology; 2012 Nov; 217(11):1067-79. PubMed ID: 22964232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes.
    Bailey EM; Choudhury A; Vuppula H; Ortiz DF; Schaeck J; Manning AM; Bosques CJ; Hoppe AD
    Front Immunol; 2020; 11():617767. PubMed ID: 33679705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering IgG1 Fc Domains That Activate the Complement System.
    Lee CH; Delidakis G
    Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.